600165 寧科生物
按盤價 
3.320 +0.070 (+2.154%) | 2026/06 - 中期 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -11.603 | -14.124 | -630.484 | -141.042 | -31.724 |
| 總資產報酬率 ROA (%) | -5.484 | -3.881 | -21.032 | -14.906 | -6.409 |
| 投入資產回報率 ROIC (%) | -6.589 | -7.569 | -55.433 | -24.808 | -9.274 | 邊際利潤分析 |
| 銷售毛利率 (%) | -6.022 | -19.955 | -19.539 | -34.621 | 0.084 |
| 營業利潤率 (%) | -48.153 | -24.842 | -162.216 | -172.692 | -39.561 |
| 息稅前利潤/營業總收入 (%) | -43.080 | -29.372 | -125.849 | -130.799 | -25.362 |
| 淨利潤/營業總收入 (%) | -48.255 | -36.648 | -167.102 | -180.357 | -40.912 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 59.806 | 147.928 | 50.916 | 60.907 | 92.316 |
| 價值變動淨收益/利潤總額(%) | 0.000 | -215.848 | 14.378 | -6.631 | -14.389 |
| 營業外收支淨額/利潤總額(%) | 0.244 | 30.105 | 3.266 | 4.302 | 1.567 | 償債能力分析 |
| 流動比率 (X) | 2.334 | 2.772 | 0.113 | 0.106 | 0.153 |
| 速動比率 (X) | 1.657 | 2.361 | 0.059 | 0.055 | 0.087 |
| 資產負債率 (%) | 48.592 | 46.346 | 88.917 | 89.665 | 75.079 |
| 帶息債務/全部投入資本 (%) | -0.156 | -0.168 | 67.900 | 59.728 | 48.212 |
| 股東權益/帶息債務 (%) | -35,292.700 | -34,638.585 | 33.560 | 10.189 | 54.847 |
| 股東權益/負債合計 (%) | 94.531 | 104.672 | 3.726 | 3.739 | 22.748 |
| 利息保障倍數 (X) | -8.300 | -4.761 | -3.008 | -2.634 | -1.710 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 71.570 | 67.173 | 64.586 | 56.537 | 15.543 |
| 存貨周轉天數 (天) | 91.204 | 74.044 | 86.287 | 95.595 | 75.511 |
| 備註： | 即時報價更新時間為 16/09/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
